More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.
A front-of-package food label would be a great educational tool. The Trump administration should keep it.
In a Senate hearing, Robert F. Kennedy, Jr. said that efforts to address the high rates of chronic disease need to start with ...
Amycretin is NVO’s unimolecular GLP-1 and amylin receptor agonist intended for once-weekly subcutaneous administration ... of three doses of amycretin in obesity patients for a total treatment ...
Russell Wooten of Hendersonville, North Carolina, has spent much of his life struggling with obesity ... of the weight-loss drugs for public employees. The Pritzker administration estimates ...
In comparison, Novo Nordisk’s current obesity drug, Wegovy, focuses on GLP-1, which influences fullness and reduces food intake. The company’s other well-known drug, Ozempic, specialises in ...
Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...